Skip to main content

Table 7 Comparison between the evaluation of response based on RECIST 1.1 and the evaluation of response based on the combined response approach

From: Predicting response to neo-adjuvant chemotherapy and assessment of residual disease in breast cancer using contrast-enhanced spectral mammography: a combined qualitative and quantitative approach

 

Sensitivity

Specificity

PPV

NPV

RECIST 1.1 evaluation

76.67% (46/60)

95% CI 63.9–86.6

66.67% (14/21)

95% CI 43.03–85.4

86.79% (46/53)

95% CI 77.9–92.4

50% (14/28)

95% CI 36.6–63.4

Combined evaluation

95.00% (57/60)

95% CI 86.08–98.9

61.90% (13/21)

95% CI 38.4–81.9

87.69% (57/65)

95% CI 80.4–92.5

81.25% (13/16}

95% CI 57.7–93.2